KROS SEC फाइलिंग - Keros Therapeutics, Inc.- वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट, प्रॉस्पेक्टस

मूलभूत आँकड़े

CIK

1664710

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Keros Therapeutics, Inc.

SEC Filings (Chronological Order)

यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।

August 28, 2025	EX-99.1	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional sign
August 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Keros Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
August 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 Keros Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
August 20, 2025	EX-99.1	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy Exhibit 99.1 Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy LEXINGTON, Mass., August 20, 2025 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunction
August 6, 2025	EX-99.2	August 2025 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of keros-exhibit9928625 August 2025 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Keros Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
August 6, 2025	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Keros Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Keros Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Empl
August 6, 2025	EX-10.2	Separation and Release Agreement by and between Keros Therapeutics, Inc. and Christopher Rovaldi, dated as of August 6, 2025. Exhibit 10.2 KEROS THERAPEUTICS, INC. 1050 Waltham Street, Suite 302 Lexington, Massachusetts 02421 August 6, 2025 Christopher Rovaldi [***] Re: Separation and Release Agreement Dear Chris: This letter sets forth the substance of the separation and release agreement (the “Agreement”) which Keros Therapeutics, Inc. (the “Company”) is offering to you to aid in your mutually agreed upon employment tr
August 6, 2025	EX-99.1	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment Exhibit 99.1 Keros to Exclusively Prioritize the Clinical Advancement of KER-065 Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., August 6, 2025 – Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on d
August 6, 2025	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2025 2024 2025 2024 REVENUE: Service and other revenue 18,168 37 34,059 120 Exhibit 99.1 Keros Therapeutics Reports Second Quarter 2025 Financial Results LEXINGTON, Mass., August 6, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the
August 6, 2025	EX-10.1	Employment Agreement by and between Keros Therapeutics, Inc. and Lorena Lerner, dated as of August 6, 2025. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), by and between Keros Therapeutics, Inc. (the “Company”), and Lorena Lerner (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), is effective as of August 6, 2025 (the “Effective Date”). R E C I T A L S WHEREAS, on May 9, 2022, the Executive was employed
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Keros Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
August 6, 2025	EX-10.3	Employment Agreement by and between Keros Therapeutics, Inc. and Esther Cho, dated as of August 6, 2025. Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), by and between Keros Therapeutics, Inc. (the “Company”), and Esther Cho (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), is effective as of August 6, 2025 (the “Effective Date”). R E C I T A L S WHEREAS, Executive has been employed by the Company on
August 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THER
July 17, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
July 17, 2025	EX-99.1	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept •Milestone payment of $10 million triggered under the global license agreement with Takeda LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing nove
July 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 9, 2025	EX-99.1	Keros Announces Return of $375 Million in Excess Capital to Stockholders Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Exhibit 99.1 Keros Announces Return of $375 Million in Excess Capital to Stockholders Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 Lexington, Mass., June 9, 2025 – Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o
June 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 6, 2025	EX-99.1	Keros Therapeutics Announces Participation at Goldman Sachs 46 Exhibit 99.1 Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference LEXINGTON, Mass., June 6, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional
May 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 29, 2025	EX-99.2	Results from the Cibotercept TROPOS PAH Phase 2 Trial May 29, 2025 TROPOS Update Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities L Results from the Cibotercept TROPOS PAH Phase 2 Trial May 29, 2025 TROPOS Update Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
May 29, 2025	EX-99.1	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities Exhibit 99.1 Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities Lexington, Mass., May 29, 2025 – Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and
May 27, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
May 19, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
May 19, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
May 19, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
May 12, 2025	EX-99.1	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference Exhibit 99.1 Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional sign
May 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 9, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State
May 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THE
May 6, 2025	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED MARCH 31, 2025 2024 REVENUE: Service and other revenue 15,891 83 License revenue 195,355 — Total revenue 211,2 Exhibit 99.1 Keros Therapeutics Reports Recent First Quarter 2025 Financial Results LEXINGTON, Mass., May 6, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of
May 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Keros Therapeutics, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission Fi
April 23, 2025	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 23, 2025	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 18, 2025	EX-10.1	Letter Agreement, dated April 17, 2025, by and between the Company and Pontifax Exhibit 10.1 Keros Therapeutics, Inc. April 17, 2025 Pontifax (Israel) IV, L.P. Pontifax (Cayman) IV, L.P. Pontifax (China) IV, L.P. Pontifax Late Stage Fund L.P. c/o Pontifax 14 Shenkar Street, Beit Ofek Herzliya Pituach, 4672514 Israel Attention: Tomer Kariv and Ran Nussbaum Ladies and Gentlemen: Keros Therapeutics, Inc., a Delaware corporation (the “Company”), and Pontifax (Israel) IV, L.P., a
April 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Keros Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
April 10, 2025	EX-3.1	Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on April 9, 2025 Exhibit 3.1 CERTIFICATE OF DESIGNATION OF RIGHTS, PREFERENCES AND PRIVILEGES OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF KEROS THERAPEUTICS, INC. The undersigned, Keith Regnante, does hereby certify: 1. That he is duly elected and acting Chief Financial Officer of Keros Therapeutics, Inc. a Delaware corporation (the “Corporation”). 2. That pursuant to the authority conferred upon the Board
April 10, 2025	EX-99.1	Keros Therapeutics Announces Review of Strategic Alternatives Exhibit 99.1 Keros Therapeutics Announces Review of Strategic Alternatives •Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., Apr. 10, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range
April 10, 2025	EX-4.1	and Computershare Trust Company, N.A., which includes the form of Certificate of Designation as Exhibit A, the form of Right Certificate as Exhibit B Exhibit 4.1 RIGHTS AGREEMENT April 9, 2025 TABLE OF CONTENTS Page SECTION 1. CERTAIN DEFINITIONS 1 SECTION 2. APPOINTMENT OF RIGHTS AGENT 8 SECTION 3. ISSUANCE OF RIGHTS 8 SECTION 4. FORM OF RIGHT CERTIFICATES 11 SECTION 5. COUNTERSIGNATURE AND REGISTRATION 11 SECTION 6. TRANSFER, SPLIT UP, COMBINATION AND EXCHANGE OF RIGHT CERTIFICATES; MUTILATED, DESTROYED, LOST OR STOLEN RIGHT CERTIFICATES 12 S
April 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
April 10, 2025	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Keros Therapeutics, Inc. (Exact name of Registr UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Keros Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 81-1173868 (State of other jurisdiction of incorporation or organization) (I.R.S. Employer I.D. No.) 1050 Wa
March 31, 2025	EX-99.2	KER-065 Update March 2025 KER-065 Update Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended KER-065 Update March 2025 KER-065 Update Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
March 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Keros Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
March 31, 2025	EX-99.1	Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers Exhibit 99.1 Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers •Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics •Clinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy (“DMD”) and other
March 6, 2025	EX-3.1	Amended and Restated Bylaws of the Registrant. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF KEROS THERAPEUTICS, INC. (A DELAWARE CORPORATION) March 5, 2025 TABLE OF CONTENTS Page Article I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 Article II CORPORATE SEAL 1 Section 3. Corporate Seal 1 Article III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 8 Section 7
March 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Keros Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
February 28, 2025	EX-99.1	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences LEXINGTON, Mass., February 28, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the
February 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Keros Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
February 26, 2025	EX-10.5	Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement for the 2020 Equity Incentive Plan. Exhibit 10.5 Keros Therapeutics, Inc. Stock Option Grant Notice (2020 Equity Incentive Plan) Keros Therapeutics, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth herein
February 26, 2025	EX-99.1	KEROS THERAPEUTICS, INC. Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2024 2023 2024 2023 REVENUE: Service and other revenue 42 143 550 151 License reven Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results LEXINGTON, Mass., February 26, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders t
February 26, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THERAPEU
February 26, 2025	EX-97	Incentive Compensation Recoupment Policy. Exhibit 97 KEROS THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. Introduction The Board of Directors (the “Board”) of Keros Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Reco
February 26, 2025	EX-21.1	Subsidiaries of Keros Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Keros Therapeutics, Inc. Name of Subsidiary Jurisdiction of Organization Keros Therapeutics Australia, Pty Ltd Australia Keros Security Corporation Massachusetts
February 26, 2025	EX-19	Insider Trading Policy. Exhibit 19 Keros Therapeutics, Inc. Insider Trading Policy I.Introduction During the course of your employment or directorship with Keros Therapeutics, Inc. (the “Company”), you may receive important information that is not yet publicly available (“inside information”) about the Company or about other publicly traded companies with which the Company has business dealings. Because of your access to
February 26, 2025	EX-4.3	Description of the Registrant’s Securities. Exhibit 4.3 DESCRIPTION OF KEROS THERAPEUTICS, INC. COMMON STOCK The following description of the common stock of Keros Therapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company’s amended and restated certifi
February 26, 2025	EX-FILING FEES	Filing fee table. Calculation of Filing Fee Tables S-8 Keros Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2020 Equity Incentive Plan, Common Stock, $0.0001 par value per share Other 1,622,188 $ 10.8536 $ 17,606,579
February 26, 2025	S-8	As filed with the Securities and Exchange Commission on February 26, 2025 As filed with the Securities and Exchange Commission on February 26, 2025 Registration No.
February 26, 2025	EX-10.24	Pharmaceuticals U.S.A., Inc., dated as of December 3, 2024. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
January 30, 2025	EX-99.1	Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference Exhibit 99.1 Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference LEXINGTON, Mass., January 30, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the tra
January 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Keros Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
January 21, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
January 21, 2025	EX-99.1	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept Exhibit 99.1 Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are
January 15, 2025	EX-99.1	Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial Exhibit 99.1 Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signali
January 15, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
January 10, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
January 10, 2025	EX-99.1	January 2025 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act o January 2025 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
December 12, 2024	EX-99.1	Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial Exhibit 99.1 Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial •Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wid
December 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Keros Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
December 10, 2024	EX-99.1	Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition Exhibit 99.1 Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition •Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeks •Durable clinical responses were associ
December 10, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
December 3, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
December 3, 2024	EX-99.1	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept Exhibit 99.1 Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., December 3, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc
November 26, 2024	EX-99.1	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional sign
November 26, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
November 6, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 6, 2024	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30, 2024 2023 2024 2023 REVENUE: Service and other revenue 388 8 508 Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results LEXINGTON, Mass., November 6, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked t
November 6, 2024	EX-99.1	Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference Exhibit 99.1 Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference LEXINGTON, Mass., November 6, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctio
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
October 16, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
October 16, 2024	EX-99.1	Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer Exhibit 99.1 Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer LEXINGTON, Mass., October 16, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional sign
October 16, 2024	EX-10.1	Employment Agreement by and between Keros Therapeutics, Inc. and Yung H. Chyung, dated as of October Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), by and between Keros Therapeutics, Inc. (the “Company”), and Yung H. Chyung (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”), is effective as of November 1, 2024 (the “Effective Date”). R E C I T A L S WHEREAS, the Company desires to employ Executive
September 30, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commis
September 3, 2024	EX-99.1	Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial Exhibit 99.1 Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial LEXINGTON, Mass., Sept. 3, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional sign
September 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
August 28, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
August 28, 2024	EX-99.1	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional sign
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THER
August 7, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
August 7, 2024	EX-99.1	August 2024 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of August 2024 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
August 7, 2024	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2024 2023 2024 2023 REVENUE: Service and other revenue 37 — 120 — Total rev Exhibit 99.1 Keros Therapeutics Reports Second Quarter 2024 Financial Results LEXINGTON, Mass., August 7, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the
August 7, 2024	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Keros Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Keros Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Empl
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 17, 2024	EX-99.1	Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association Exhibit 99.1 Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association •Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden •Durable clinical responses were associated with improvements in pa
June 17, 2024	EX-99.2	Corporate Update June 2024 June 2024 Corporate Update Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 199 Corporate Update June 2024 June 2024 Corporate Update Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
June 17, 2024	EX-99.1	Keros Therapeutics Announces Leadership Updates Exhibit 99.1 Keros Therapeutics Announces Leadership Updates LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the tr
June 17, 2024	424B5	Up to $350,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279094 PROSPECTUS SUPPLEMENT (To Prospectus dated May 3, 2024) Up to $350,000,000 Common Stock We have previously entered into a sales agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated May 3, 2021, pursuant to which we may offer and sell shares of our common stock, $0.0001 par value per share, from time to
June 17, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 17, 2024	EX-1.1	Sales Agreement, dated May 3, 2021, by and between the Registrant and Leerink Partners (formerly SVB Leerink LLC) Exhibit 1.1 Keros Therapeutics, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT May 3, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Keros Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1. Issuance and Sale of
June 17, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 17, 2024	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) Keros Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Keros Therapeutics, Inc.
June 17, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 4, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 4, 2024	EX-99.1	Keros Therapeutics to Host a Corporate Update Conference Call and Webcast Exhibit 99.1 Keros Therapeutics to Host a Corporate Update Conference Call and Webcast LEXINGTON, Mass., June 4, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunct
June 3, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 3, 2024	EX-99.1	Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference Exhibit 99.1 Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference LEXINGTON, Mass., June 3, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunc
May 30, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 28, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 28, 2024	EX-99.1	Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors Exhibit 99.1 Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signali
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THE
May 8, 2024	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED MARCH 31, 2024 2023 REVENUE: Service and other revenue 83 — Total revenue 83 — OPERATING EXPENSES: Research an Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results LEXINGTON, Mass., May 8, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dys
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission Fi
May 3, 2024	EX-4.8	Form of Preferred Stock Warrant Agreement and Warrant Certificate Exhibit 4.8 KEROS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF KEROS THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [l], between KEROS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [l], a [corporation] [national banking association] organized and
May 3, 2024	EX-4.7	Form of Common Stock Warrant Agreement and Warrant Certificate Exhibit 4.7 KEROS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF KEROS THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between KEROS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing
May 3, 2024	EX-4.9	Form of Debt Securities Warrant Agreement and Warrant Certificate Exhibit 4.9 KEROS THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF KEROS THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between KEROS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and
May 3, 2024	EX-4.4	Form of Indenture Exhibit 4.4 Keros Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [l], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 7 Se
May 3, 2024	EX-FILING FEES	iling Fee Table. Exhibit 107 Calculation of Registration Fee Form S-3 (Form Type) Keros Therapeutics, Inc.
May 3, 2024	S-3ASR	As filed with the Securities and Exchange Commission on May 3, 2024 As filed with the Securities and Exchange Commission on May 3, 2024 Registration No.
April 17, 2024	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 17, 2024	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Keros Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
March 14, 2024	EX-99.1	Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes Exhibit 99.1 Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to
March 6, 2024	EX-99.1	March 2024 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of March 2024 Corporate Presentation Corporate Presentation Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
March 6, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
March 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Keros Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
March 5, 2024	EX-99.1	Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference Exhibit 99.1 Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference LEXINGTON, Mass., March 5, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the
March 5, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
February 29, 2024	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 Keros Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity 2020 Equity Incentive Plan, Common Stock, $0.0001 par value per shar
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.
February 28, 2024	EX-4.3	Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF KEROS THERAPEUTICS, INC. COMMON STOCK The following description of the common stock of Keros Therapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company’s amended and restated certifi
February 28, 2024	EX-21.1	Subsidiaries of Keros Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Keros Therapeutics, Inc. Name of Subsidiary Jurisdiction of Organization Keros Therapeutics Australia, Pty Ltd Australia Keros Security Corporation Massachusetts
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Keros Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
February 28, 2024	EX-99.1	KEROS THERAPEUTICS, INC. Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2023 2022 2023 2022 REVENUE: Service and other revenue 143 — 151 — Total revenue 14 Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results LEXINGTON, Mass., February 28, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders t
February 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THERAPEU
February 28, 2024	EX-97	Incentive Compensation Recoupment Policy. Exhibit 97 KEROS THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. Introduction The Board of Directors (the “Board”) of Keros Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Reco
February 28, 2024	EX-10.12	Amendment No. 4 dated as of April 12, 2023, to License Agreement by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd. Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE KEROS THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO KEROS THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. AMENDMENT NO. 4 TO LICENSE AGREEMENT This AMENDMENT NO. 4 (this “Amendment”) is entered into as of April 12, 20
February 13, 2024	SC 13G/A	KROS / Keros Therapeutics, Inc. / ALKEON CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 kros13ga2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Keros Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 492327101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the app
January 9, 2024	EX-99.1	Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock Exhibit 99.1 Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock LEXINGTON, Mass., Jan. 9, 2024 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of
January 9, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
January 4, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
January 4, 2024	424B5	3,500,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-255724 Prospectus Supplement (To Prospectus dated May 3, 2021) 3,500,000 Shares Common Stock We are offering 3,500,000 shares of our common stock to be sold in the offering. Our common stock is listed on The Nasdaq Global Market under the symbol “KROS.” On January 3, 2024, the last reported sale price of our common stock as reported on The Nasd
January 4, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Keros Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Keros Therapeutics, Inc.
January 4, 2024	EX-1.1	, 2024, by and among the Company, Goldman Sachs & Co. LLC, Leerink Partners LLC, Piper Sandler & Co. and Truist Securities, Inc Exhibit 1.1 Execution Version 3,500,000 Shares Keros Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT January 3, 2024 GOLDMAN SACHS & CO. LLC LEERINK PARTNERS LLC PIPER SANDLER & CO. TRUIST SECURITIES, INC. As Representatives of the several Underwriters c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachuse
January 3, 2024	EX-99.1	January 2024 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act January 2024 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
January 3, 2024	EX-99.2	Keros Therapeutics to Develop KER-065 for the Treatment of Obesity Exhibit 99.2 Keros Therapeutics to Develop KER-065 for the Treatment of Obesity •Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers •Keros expects to report initial data from this Phase 1 clinical trial in the first quarter of 2025 •Preclinical data showed potential proof-o
January 3, 2024	424B5	Subject to Completion, dated January 3, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-255724 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities and are not soliciting an offer to buy the securities in any jurisdiction where the offer or sale is not permitted. Subject to Complet
January 3, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
December 13, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ss2818988ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 3 to the Statement on Schedule 13D, dated December 11, 2023, with respect to the common stock, par value $0.0001 per share, of Keros Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Secu
December 13, 2023	SC 13D/A	KROS / Keros Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Keros Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 492327101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022
December 11, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
December 11, 2023	EX-99.2	Hematology Franchise: Update at 65th Annual Congress of the American Society of Hematology December 2023 Hematology Franchise Update 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking stat Hematology Franchise: Update at 65th Annual Congress of the American Society of Hematology December 2023 Hematology Franchise Update 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
December 11, 2023	EX-99.1	Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition Exhibit 99.1 Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition •KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burden •Durable clinical responses were associated with improvements in patient-reported measures of fatigue •Biomarker
November 7, 2023	EX-99.1	Keros Therapeutics to Present at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics to Present at Upcoming Healthcare Conferences LEXINGTON, Mass., November 7, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming g
November 7, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 6, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 6, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 6, 2023	EX-99.1	November 2023 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Ac November 2023 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
November 6, 2023	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30, 2023 2022 2023 2022 REVENUE: Service revenue $ 8 $ — $ 8 $ — Tot Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results November 6, 2023 at 8:00 AM EST LEXINGTON, Mass., November 6, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Keros Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
October 4, 2023	EX-99.1	Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society Exhibit 99.1 Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society LEXINGTON, Mass., October 4, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with
September 5, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
September 5, 2023	EX-99.1	Keros Therapeutics to Present at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics to Present at Upcoming Healthcare Conferences LEXINGTON, Mass., September 5, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming
August 7, 2023	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED JUNE 30, SIX MONTHS ENDED JUNE 30, 2023 2022 2023 2022 OPERATING EXPENSES: Research and development (32,534) ( Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results August 7, 2023 at 8:00 AM EST LEXINGTON, Mass., August 07, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients wi
August 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
August 7, 2023	EX-99.2	August 8, 2023 KER-012 Update KER-012 Update 2 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of exhibit992 August 8, 2023 KER-012 Update KER-012 Update 2 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THER
August 7, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
August 7, 2023	EX-99.1	August 2023 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act exhibit991 August 2023 Corporate Presentation Corporate Presentation 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
July 24, 2023	EX-99.1	Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension Exhibit 99.1 Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension •Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with background therapy in
June 9, 2023	EX-99.2	June 9, 2023 Hematology Franchise: Program Updates and Summary of Data Presented at 28th Annual Congress of the European Hematology Association Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “ eha2023kerosinvestorcal June 9, 2023 Hematology Franchise: Program Updates and Summary of Data Presented at 28th Annual Congress of the European Hematology Association Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
June 9, 2023	EX-99.1	Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association Exhibit 99.1 Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association •Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to provide an update on its hematology franchise. Lexin
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 7, 2023	EX-99.1	Keros Therapeutics to Present at Goldman Sach’s 44 Exhibit 99.1 Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference LEXINGTON, Mass., June 7, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular di
June 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
June 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 22, 2023	EX-99.1	Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference Exhibit 99.1 Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference LEXINGTON, Mass., May 22, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THE
May 4, 2023	EX-10.2	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.2 Keros Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Keros Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Empl
May 4, 2023	EX-10.1	egistrant and Revolution Labs Owner, LLC, dated January 6, 2023. Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (this “Amendment”) is made as of this 6th day of January, 2023 (the “Execution Date”) by and between REVOLUTION LABS OWNER, LLC, a Delaware limited liability company (“Landlord”), and KEROS THERAPEUTICS, INC., a Delaware corporation (“Tenant”). WITNESSETH: Reference is hereby made to the following facts: A. Landlord and Tenant are
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Keros Therapeutics, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission Fi
May 4, 2023	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED MARCH 31, 2023 2022 REVENUE: License revenue $ — $ — Total revenue — — OPERATING EXPENSES: Research and develo EX-99.1 2 exhibit991q12023.htm EX-99.1 Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results LEXINGTON, Mass., May 4, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients
April 24, 2023	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 24, 2023	DEFA14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 Keros Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
April 19, 2023	EX-99.1	Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors Exhibit 99.1 Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors April 19, 2023 at 8:00 AM EDT LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological
March 3, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 Keros Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity 2020 Equity Incentive Plan, Common Stock, $0.0001 par value per shar
March 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
March 3, 2023	EX-10.11	Amendment No. 2, dated as of March 11, 2022, and Amendment No. 3, dated as of December 11, 2022, to License Agreement by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd. Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE KEROS THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO KEROS THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. AMENDMENT NO. 2 TO LICENSE AGREEMENT This AMENDMENT NO. 2 (this “Amendment”) is entered into as of March 11, 20
March 3, 2023	EX-99.1	KEROS THERAPEUTICS, INC. Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED DECEMBER 31, YEAR ENDED DECEMBER 31, 2022 2021 2022 2021 REVENUE: Research collaboration revenue $ — $ 20,000 $ — $ 20,1 Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results LEXINGTON, Mass., March 3, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematol
March 3, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THERAPEU
March 3, 2023	S-8	As filed with the Securities and Exchange Commission on March 3, 2023 As filed with the Securities and Exchange Commission on March 3, 2023 Registration No.
March 3, 2023	EX-21.1	Subsidiaries of Keros Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Keros Therapeutics, Inc. Name of Subsidiary Jurisdiction of Organization Keros Therapeutics Australia, Pty Ltd Australia Keros Security Corporation Massachusetts
March 3, 2023	EX-4.3	Exhibit 4.3 Exhibit 4.3 DESCRIPTION OF KEROS THERAPEUTICS, INC. COMMON STOCK The following description of the common stock of Keros Therapeutics, Inc., or the Company, is a summary and does not purport to be complete. This summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the Company’s amended and restated certifi
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Keros Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
March 1, 2023	EX-99.1	Keros Therapeutics to Present at Cowen’s 43 Exhibit 99.1 Keros Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference LEXINGTON, Mass., March 1, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with
February 14, 2023	SC 13G/A	KROS / Keros Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-kros123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* KEROS THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 492327101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch
February 13, 2023	SC 13G/A	KROS / Keros Therapeutics, Inc. / ALKEON CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 kros13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Keros Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 492327101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri
February 7, 2023	EX-99.1	Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference Exhibit 99.1 Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference LEXINGTON, Mass., February 7, 2023 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorde
February 7, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
February 2, 2023	SC 13G/A	KROS / Keros Therapeutics, Inc. / Arkin Moshe - SC 13G/A Passive Investment SC 13G/A 1 zk2923109.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Keros Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 492327101 (CUSIP Number) January 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
January 9, 2023	EX-99.1	January 2023 Corporate Presentation Disclaimer 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as EX-99.1 2 keroscorporatedeck-jan20.htm EX-99.1 January 2023 Corporate Presentation Disclaimer 2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “potential,” "project
January 9, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
January 6, 2023	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissio
December 12, 2022	EX-FILING FEES	Calculation of Filing Fee Tables Form S-3 (Form Type) Keros Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities EX-FILING FEES 2 exhibit107-424b5.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Keros Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggre
December 12, 2022	EX-99.1	Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition Exhibit 99.1 Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition ?Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) - Keros Th
December 12, 2022	424B5	Up to $250,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-255724 PROSPECTUS SUPPLEMENT (To Prospectus dated May 3, 2021) Up to $250,000,000 Common Stock We have previously entered into a sales agreement, or the sales agreement, with SVB Securities LLC (formerly known as SVB Leerink LLC), or SVB Securities, dated May 3, 2021, pursuant to which we may offer and sell shares of our common stock, $0.0001 p
December 12, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
December 12, 2022	EX-99.2	December 12, 2022 Hematology Franchise: Update of Data Presented at 64th Annual Congress of the American Society of Hematology Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking s December 12, 2022 Hematology Franchise: Update of Data Presented at 64th Annual Congress of the American Society of Hematology Disclaimer Statements contained in this presentation regarding matters that are not historical facts are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
December 12, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
November 22, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
November 22, 2022	EX-99.1	Keros Therapeutics to Present at Upcoming Healthcare Conferences Exhibit 99.1 Keros Therapeutics to Present at Upcoming Healthcare Conferences November 22, 2022 at 8:00 a.m. EST LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (?Keros?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardi
November 7, 2022	SC 13D/A	KROS / Keros Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Keros Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 492327101 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022
November 7, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 7, 2022	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 3, 2022, with respect to the common stock, par value $0.
November 7, 2022	EX-99.1	Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions Exhibit 99.1 Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions November 7, 2022, 4:01 PM EST LEXINGTON, Mass., Nov. 7, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (?Keros?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for
November 3, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 3, 2022	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED SEPTEMBER 30, NINE MONTHS ENDED SEPTEMBER 30, 2022 2021 2022 2021 REVENUE: License revenue $ — $ — $ — $ 100 T Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results LEXINGTON, Mass., November 3, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (?Keros? or the ?Company?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulm
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commissi
November 3, 2022	EX-99.1	Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047 Exhibit 99.1 Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047 November 3, 2022 at 9:00 AM ET LEXINGTON, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (?Keros?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the di
November 3, 2022	EX-10.1	Amendment to Offer Letter by and between the registrant and Jennifer Lachey, dated August 1, 2022. Exhibit 10.1 99 Hayden Avenue Bldg. E, Suite 120 Lexington MA 02421 Jennifer Lachey August 1, 2022 Re: Change in Terms of Employment with Keros Therapeutics, Inc. Dear Jennifer: As discussed, and at your request, this offer letter agreement (the ?Agreement?) sets forth the revised terms and conditions of your employment with Keros Therapeutics, Inc. (the ?Company?). These terms shall go into on Se
September 12, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commis
September 12, 2022	EX-99.1	Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting Exhibit 99.1 Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting LEXINGTON, Mass., September 12, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (?Keros?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an
September 6, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commiss
September 6, 2022	EX-99.1	Keros Therapeutics to Present at the Morgan Stanley 20 Exhibit 99.1 Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference LEXINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) - Keros Therapeutics, Inc. (?Keros?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoske
August 4, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
August 4, 2022	EX-99.1	KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high transfusion burden patients achieved transfusion in Exhibit 99.1 Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results KER-050 data from ongoing Phase 2 study in patients with lower risk myelodysplastic syndromes demonstrated meaningful responses across both ring sideroblast-positive and non-RS patients; 44% of high transfusion burden patients achieved transfusion independence KER-012 preliminary Phase 1 da
August 4, 2022	EX-99.1	August 2022 Corporate Presentation Disclaimer Statements contained in this presentation by Keros Therapeutics, Inc. ("Keros", "we" or "our") regarding matters that are not historical facts are “forward- looking statements” within the meaning of the P August 2022 Corporate Presentation Disclaimer Statements contained in this presentation by Keros Therapeutics, Inc.
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THER
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 13, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 13, 2022	EX-99.1	Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions Exhibit 99.1 Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions Lexington, Mass. ? June 13, 2022 ? Keros Therapeutics, Inc. (?Keros? or the ?Company?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and
June 10, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission
June 10, 2022	EX-99.1	Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27 Exhibit 99.1 Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association ?Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time. Lexington, Mass. ? June 10, 2022 ? Keros Therapeutics,
June 10, 2022	EX-99.2	June 2022 KER-050 Update Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Wor June 2022 KER-050 Update Disclaimer Statements contained in this presentation regarding matters that are not historical facts are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
June 1, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 18, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 18, 2022	EX-99.1	Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers Exhibit 99.1 Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers LEXINGTON, Mass., ? May 18, 2022 ? Keros Therapeutics, Inc. (?Keros?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologica
May 18, 2022	EX-99.2	Corporate Update May 2022 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Wo Corporate Update May 2022 Disclaimer Statements contained in this presentation regarding matters that are not historical facts are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
May 17, 2022	EX-99.1	Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference Exhibit 99.1 Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference Lexington, Mass. ? May 17, 2022 ? Keros Therapeutics, Inc. (?Keros? or the ?Company?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatme
May 17, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission F
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39264 KEROS THE
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Keros Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39264 81-1173868 (state or other jurisdiction of incorporation) (Commission Fi
May 5, 2022	EX-99.1	KEROS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) THREE MONTHS ENDED MARCH 31, 2022 2021 OPERATING EXPENSES: Research and development (18,078) (11,495) General and administrative Exhibit 99.1 Keros Therapeutics Reports First Quarter 2022 Financial Results Lexington, Mass. ? May 5, 2022 ? Keros Therapeutics, Inc. (?Keros? or the ?Company?) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical nee

KROS / Keros Therapeutics, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

मूलभूत आँकड़े

SEC Filings

SEC Filings (Chronological Order)